Omnicell (OMCL) investor relations material

Executive summary

• Achieved strong Q4 and FY 2025 results, with total revenues of $314M for Q4 (up 2% YoY) and $1.185B for the year (up 7% YoY), both above the midpoint of guidance.

• Launched Titan XT, a next-generation automated dispensing system, and expanded the OmniSphere cloud platform, targeting enhanced medication management and automation.

• Focused on expanding market presence, scaling recurring revenue, and accelerating technology innovation, with SaaS and Expert Services projected to comprise 22% of 2026 revenue.

• Robust demand from major health systems, government facilities, and competitive wins across the U.S. and Canada.

• Recognized as a Top 50 Healthcare Technology Company and for ESG performance.

Financial highlights

• Q4 2025 total revenue: $314M, up 2% YoY; FY 2025 total revenue: $1.185B, up 7% YoY.

• Q4 2025 non-GAAP gross margin: 43.2% (down from 47.4% YoY); Q4 non-GAAP EBITDA: $37M (11.7% margin).

• Q4 2025 GAAP EPS: -$0.05; non-GAAP EPS: $0.40; FY 2025 GAAP EPS: $0.04; non-GAAP EPS: $1.62.

• FY 2025 recurring revenue represented 52% of total revenue; ARR at year-end: $636M, up 10% YoY.

• Year-end cash and equivalents: $197M; free cash flow Q4: $18M; product backlog: $640M.

Outlook and guidance

• FY 2026 revenue guidance: $1.215B–$1.255B; product bookings: $510M–$560M; ARR: $680M–$700M.

• FY 2026 non-GAAP EBITDA: $145M–$160M; non-GAAP EPS: $1.65–$1.85; SaaS and Expert Services revenue: $265M–$275M.

• Q1 2026 revenue guidance: $300M–$310M; non-GAAP EBITDA: $27M–$33M; non-GAAP EPS: $0.26–$0.36.

• Guidance includes $15M in tariff costs and a 13% effective tax rate.

• Titan XT expected to ship in H2 2026; OmniSphere software enhancements available H1 2027.